Gut microbiota in patients with non-alcoholic fatty liver disease

We used a high-throughput amplicon sequencing of 16S rRNA V3-V4 region on the Illumina MiSeq platform, in samples collected from subjects with NAFLD and healthy controls to determine the influence of the gut microbiotas on progression of nonalcoholic liver disease.

本研究采用伊卢米纳（Illumina）MiSeq测序平台，针对16S核糖体RNA（16S rRNA）V3-V4可变区进行高通量扩增子测序，以采集自非酒精性脂肪性肝病（NAFLD）患者与健康对照受试者的样本为研究对象，旨在明确肠道微生物群对非酒精性肝病进展的影响。